| [November 01, 2017] |
 |
FDA Grants Fast Track Designation to Visterra's VIS410 for Treatment of Hospitalized Patients with Influenza A
Visterra,
Inc. today announced that the U.S. Food and Drug Administration
(FDA) has granted Fast Track designation to its lead product candidate, VIS410,
a novel monoclonal antibody in development for the treatment of
hospitalized patients with influenza A. Visterra is a clinical-stage
biotechnology company that uses its novel Hierotope®
platform to identify unique disease targets and to design and
engineer precision antibody-based biological medicines against such
targets that are not adequately addressed with conventional approaches.
"We are pleased that the FDA has granted Fast Track designation to
VIS410," said Brian
J.G. Pereira, M.D., president and chief executive officer of
Visterra. "Severe influenza A is a serious disease, particularly
dangerous in individuals with compromised immune systems, leading to as
many as 700,000 hospitalizations and 56,000 deaths annually in the U.S.1
We are developing VIS410 as a single-dose treatment, and plan to
initiate a Phase 2b clinical trial in hospitalized patients with
influenza A in early 2018."
Fast Track is the FDA process designed to facilitate the development and
expedite the review of investigational drugs to treat serious conditions
and fill an unmet medical need. When granting Fast Track designation,
the FDA evaluates whether a drug will affect factors such as survival,
day-to-day functioning, or the likelihood that the disease, if left
untreated, will progress to a more serious condition. With Fast Track
designation, early and frequent communications between the FDA and the
sponsor is encouraged throughout the drug development and review process
to help to ensure that questions are resolved quickly, often leading to
earlier dru approval.
About VIS410
Visterra's lead product candidate, VIS410,
is a monoclonal antibody designed and engineered to target all known
strains of influenza A and is being developed as a single-dose
administration for the treatment of hospitalized patients with influenza
A. VIS410 is directed against a specific epitope, called the Hierotope,
on hemagglutinin, which is a surface protein of influenza viruses used
for binding and entry into cells. VIS410 is designed to prevent fusion
of the influenza virus with host cell membranes by binding to
hemagglutinin and thereby terminating the viral replication cycle.
Visterra is currently conducting a Phase 2a clinical trial of VIS410 in
ambulatory patients with influenza A, with funding through contract
number HHSO100201500018C from the Biomedical Advanced Research and
Development Authority (BARDA), part of the Office of the Assistant
Secretary for Preparedness and Response within the U.S. Department of
Health and Human Services. Visterra plans to initiate a Phase 2b
clinical trial in hospitalized patients with influenza A in early 2018.
About Visterra
Visterra
is a clinical-stage biopharmaceutical company focused on applying its
novel Hierotope®
platform to identify unique disease targets and to design and
engineer precision antibody-based biological medicines against such
targets that are not adequately addressed with conventional approaches.
These targets include infectious organisms such as viruses, bacteria and
fungi, which have a high degree of diversity among strains with frequent
mutations. Visterra's technology is also uniquely capable of engineering
biological medicines that selectively modify the activity of endogenous
targets that have limited surface area, are hard to access, have dynamic
structures, and/or are similar to other proteins in the body that should
be avoided. In addition to VIS410,
the company's other product candidates are VIS513,
a monoclonal antibody in development as a single-dose administration for
the treatment of dengue, VIS649,
a monoclonal antibody in development for the treatment of IgA
nephropathy, and VIS705,
an antibody-drug conjugate being developed as a single-dose curative
therapy, engineered to kill all strains of the deadly Pseudomonas aeruginosa
bacteria, including potentially multi-drug resistant strains. In
addition, Visterra has applied its Hierotope platform to develop novel
modifications to the Fc region of an antibody, to enhance half-life by
as much as ten-fold while maintaining and often improving effector
function. These capabilities, called ViStar™ antibody Fc engineering,
support the development of long-acting monoclonal antibodies for the
extended protection in infectious diseases and less frequent
administration in chronic diseases. For more information, visit www.visterrainc.com.
1 Centers for Disease Control and Prevention, Estimated
Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths
Averted by Vaccination in the United States, Seasonal Influenza (Flu)
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005496/en/
[ Back To TMCnet.com's Homepage ]
|
